| Literature DB >> 30043913 |
Kadir Kaan Özsin1, Umut Serhat Sanrı1, Faruk Toktaş1, Nail Kahraman1, Şenol Yavuz1.
Abstract
OBJECTIVE: Postoperative atrial fibrillation (PoAF) is a common complication after coronary artery bypass grafting (CABG). The aim of the present study was to evaluate the association between development of PoAF and vitamin D levels in patients undergoing isolated CABG.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30043913 PMCID: PMC6089122 DOI: 10.21470/1678-9741-2017-0214
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Demographic features of the patients.
| PoAF(+) group | PoAF(-) group | ||
|---|---|---|---|
| Age (years) | 61.94±10.88 | 58.18±10.98 | 0.089 |
| Age ≥ 65 years, n (%) | 22 (44) | 12 (24) | 0.035 |
| Male gender, n (%) | 37 (74) | 33 (66) | 0.383 |
| Hypertension, n (%) | 26 (52) | 22 (44) | 0.423 |
| Diabetes mellitus, n (%) | 23 (46) | 21 (42) | 0.687 |
| Beta-blocker therapy, n (%) | 38 (76) | 32 (64) | 0.190 |
| Statin therapy, n (%) | 31 (62) | 29 (58) | 0.683 |
| ACE-I/ARB therapy, n (%) | 22 (44) | 20 (40) | 0.685 |
| BSA | 1.85±0.16 | 1.87±0.16 | 0.719 |
| BMI | 27.69±4.48 | 27.56±4.06 | 0.881 |
Student's t test; Pearson Chi-square
ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor blocker; BMI=body mass index; BSA=body surface area; PoAF=postoperative atrial fibrillation
Laboratory and operative variables.
| PoAF group | PoAF(-) group | ||
|---|---|---|---|
| Hematocrit (%) | 39.37±5.53 | 41.16±4.69 | 0.244 |
| White blood cell (103/µL) | 9.18±2.14 | 9.55±2.87 | 0.733 |
| Platelet (103/µL) | 268.98±91.2 | 237.56±54.69 | 0.126 |
| Red cell distribution width (%) | 13.76±1.13 | 13.98±1.25 | 0.456 |
| Mean platelet volume (fL) | 8.91±0.98 | 8.66±0.86 | 0.208 |
| BUN (mg/dL) | 18.04±7.71 | 17.78±7.39 | 0.803 |
| Creatinine (mg/dL) | 0.88±0.21 | 0.89±0.32 | 0.545 |
| Na (mEq/L) | 138.3±3.07 | 138.64±2.46 | 0.534 |
| K (mEq/L) | 4.17±0.42 | 4.14±0.6 | 0.673 |
| Ca (mg/dL) | 9.09±0.42 | 9.17±0.51 | 0.269 |
| Mg (mg/dL) | 1.91±0.15 | 1.9±0.22 | 0.816 |
| Free T3 (pg/mL) | 2.94±0.45 | 2.95±0.44 | 0.959 |
| Free T4 (ng/dL) | 1.11±0.19 | 1.17±0.21 | 0.166 |
| TSH (IU/mL) | 1.96±1.19 | 2.92±4.72 | 0.608 |
| C reactive protein (mg/dL) | 14.73±23.40 | 12.7±19.09 | 0.871 |
| Total cholesterol (mg/dl) | 202.5±33.41 | 197.92±39.96 | 0.536 |
| LDL-C (mg/dL) | 128.11±29.44 | 119.37±33.57 | 0.596 |
| HDL-C (mg/dL) | 43.38±8.36 | 41.55±8.43 | 0.316 |
| TG (mg/dL) | 153.38±65.66 | 184.44±111.41 | 0.237 |
| 25(OH) vitamin D (ng/mL) | 7.49±3.81 | 12.13±7.98 | 0.002 |
| Ejection fraction (%) | 51.14±9.09 | 50.20±9.42 | 0.648 |
| Left atrium diameter (mm) | 38.40±4.22 | 38.08±4.15 | 0.928 |
| ACC time (min) | 58.32±14.99 | 57.04±14.38 | 0.473 |
| CPB time (min) | 88.04±20.99 | 86.72±1947 | 0.745 |
Student's-t test; Mann-Whitney U test
25(OH) vitamin D=25-hydroxy vitamin D; ACC=aortic cross clamp; BUN=Blood urea nitrogen; CPB=cardiopulmonary bypass; HDL-C=high density lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol; PoAF=postoperative atrial fibrillation; T3=triiodothyronine; T4=thyroxine; TG=triglyceride; TSH=thyroid-stimulating hormone
Binary logistic regression analysis to identify predictors of PoAF.
| Univariate Analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables |
| Exp(B) | 95% C.I. |
| Exp(B) | 95% C.I. |
| Age | 0.091 | 1.032 | 0.995-1.071 | |||
| Age ≥ 65 years | 0.037 | 0.402 | 0.171 - .946 | 0.013 | 3.525 | 1.310-9.483 |
| HT | 0.424 | 1.379 | 0.628-3.029 | |||
| DM | 0.687 | 1.176 | 0.534-2.593 | |||
| EF | 0.609 | 1.011 | 0.969-1.055 | |||
| LAD | 0.700 | 1.019 | 0.927-1.120 | |||
| 25(OH) Vitamin D | 0.002 | 0.867 | 0.793 - .949 | 0.001 | 0.855 | 0.780-0.938 |
| CPB time | 0.742 | 1.003 | 0.984 -1.023 | |||
25(OH) vitamin D = 25-hydroxy vitamin D; CPB=cardiopulmonary bypass; DM=diabetes mellitus; EF=ejection fraction; HT=hypertension; LAD=left atrium diameter; PoAF=postoperative atrial fibrillation
Fig. 1Receiver operation characteristic (ROC) curve and the area under the curve (AUC) for vitamin D levels for predicting PoAF.
| Abbreviations, acronyms & symbols | |
|---|---|
| 25(OH) vitamin D | = 25-hydroxy vitamin D |
| ACE | = Angiotensin-converting enzyme |
| AF | = Atrial fibrillation |
| ARB | = Angiotensin receptor blocker |
| CABG | = Coronary artery bypass grafting |
| CI | = Confidence interval |
| COPD | = Chronic obstructive pulmonary disease |
| CPB | = Cardiopulmonary bypass |
| ECG | = Electrocardiography |
| ICU | = Intensive care unit |
| OR | = Odds ratio |
| PoAF | = Postoperative atrial fibrillation |
| RAAS | = Renin-angiotensin-aldosterone system |
| ROC | = Receiver-operating characteristic curve |
| Authors' roles & responsibilities | |
|---|---|
| KKÖ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| USS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| FT | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| NK | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| ŞY | Drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |